Evaluating renal dysfunction as a risk factor for sudden cardiac death

FHS
July 29, 2024
5:09 pm

Patients with congestive heart failure (CHF) having a compromised blood supply, are at greater risk of sudden cardiac death (SCD).

Verrica receives FDA approval for YCANTH to treat molluscum

Molluscum contagiosum, or water wart. Credit: E van Herk / commons.wikimedia.org. Verrica Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for

July 24, 2023

Novo-partnered 3D bioprinting biotech gets $70M+ from Canadian government

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 11, 2024

Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID | Psychedelic Invest

TORONTO, June 12, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused

June 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.